Prevalence of *Clostridium difficile* Infection among Solid Organ Transplant Recipients: A Meta-Analysis of Published Studies

Suresh Paudel, Ioannis M. Zacharioudakis, Fainareti N. Zervou, Panayiotis D. Ziakas, Eleftherios Mylonakis*

Infectious Diseases Division, Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, Rhode Island, United States of America

* emylonakis@lifespan.org

Abstract

Several factors including antibiotic use, immunosuppression and frequent hospitalizations make solid organ transplant (SOT) recipients vulnerable to *Clostridium difficile* infection (CDI). We conducted a meta-analysis of published studies from 1991-2014 to estimate the prevalence of CDI in this patient population. We searched PubMed, EMBASE and Google Scholar databases. Among the 75,940 retrieved citations, we found 30 studies coded from 35 articles that were relevant to our study. Based on these studies, we estimated the prevalence of CDI among 21,683 patients who underwent transplantation of kidney, liver, lungs, heart, pancreas, intestine or more than one organ and stratified each study based on the type of transplanted organ, place of the study conduction, and size of patient population. The overall estimated prevalence in SOT recipients was 7.4% [95%CI, (5.6-9.5%)] and it varied based on the type of organ transplant. The prevalence was 12.7% [95%CI, (6.4%-20.9%)] among patients who underwent transplantation for more than one organ. The prevalence among other SOT recipients was: lung 10.8% [95% CI, (5.5%-17.7%)], liver 9.1 % [95%CI, (5.8%-13.2%)], intestine 8% [95% CI, (2.6%-15.9%)], heart 5.2% [95%CI, (1.8%-10.2%)], kidney 4.7% [95% CI, (2.6%-7.3%)], and pancreas 3.2% [95% CI, (0.5%-7.9%)]. Among the studies that reported relevant data, the estimated prevalence of severe CDI was 5.3% [95% CI (2.3%-9.3%)] and the overall recurrence rate was 19.7% [95% CI, (13.7%-26.6%)]. In summary, CDI is a significant complication after SOT and preventive strategies are important in order to reduce the CDI related morbidity and mortality.

Introduction

*Clostridium difficile* is the most common cause of hospital-acquired infections [1]. Recent studies report the prevalence of *Clostridium difficile* infection (CDI) among hospitalized patients to be 0.9% [2]. Studies have reported an increase in hospitalization rates associated with *C. difficile* infection (CDI) [3]. There has also been a remarkable increase in mortality among CDI
patients in hospitals [4], as mortality from CDI increased five-fold from 1999/2000-2005/2006 [5] and CDI accounts for ≥ $4.8 billion in excess health-care costs [6].

Solid organ transplant (SOT) recipients are at high risk for CDI because of impaired defense mechanisms resulting from immunosuppression, perioperative antibiotic use and organ failure [7–9]. A study among 49,198 SOT recipients that used data from the 2009 US inpatient sample database noted that these patients are at greater risk for CDI compared to the general hospital population and estimated the prevalence of infection in SOT patients to be 2.7% [10]. However, this earlier study captured CDI episodes that occurred in an indeterminate time after transplantation and did not provide data for the initial hospitalization period post-transplantation where the most CDI episodes are expected to occur. In order to address these issues, we performed a meta-analysis to estimate the prevalence of CDI in SOT patients during the peri-transplant and post-transplantation period in university-based, tertiary medical centers. Also, we aimed to stratify the results based on type of the organ transplanted and estimate the recurrence rate and severity of CDI in this specific patient population.

Materials and Methods

Study Selection

We (S.P and I.M.Z) searched PubMed (1978 to February 2015), EMBASE and Google Scholar databases to identify studies that reported the prevalence of CDI among SOT recipients. The concise search term for PubMed was transplant AND (clostrid OR difficile OR diarrhea OR infect OR (clostridium difficile) OR (pseudomembranous colitis)). The terms infect and diarrhea were included in the search term in order to retrieve all articles that report episodes of CDI along with other infections, as well as episodes of CDI along with other causes of diarrhea in SOT patients. Articles that were considered eligible by title and abstract reading were assessed in full text. The reference lists of the eligible studies were also reviewed to find possible studies that match our search. Our meta-analysis follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (S1 Table) [11].

Inclusion Criteria

Only studies that reported the prevalence of CDI among SOT patients during the peri-transplant period were included. Peri-transplant period was defined as “the time of transplant to the first discharge from the hospital” [12]. Studies that did not include follow-up of patients during the initial hospitalization post transplantation were excluded. Studies with adequate quality as described below in the Quality Assessment section were included. Also, studies published in a language other than English were excluded from the analysis.

Outcomes of Interest

The primary outcome of interest of this meta-analysis was the prevalence of CDI among SOT patients. CDI was defined as “the presence of symptoms (usually diarrhea) and either a stool test result positive for C. difficile toxins or toxigenic C. difficile or colonoscopic findings demonstrating pseudomembranous colitis” [13]. Prevalence was calculated as the proportion of the patients diagnosed with CDI among the patients “at risk”, i.e. patients who received solid organ transplantation. A subgroup analysis was performed according to the type of organ transplanted, location of study conduction, and size of study population.
Data Extraction

Studies that were considered for inclusion in the meta-analysis were evaluated by two reviewers (S.P. and I.M.Z.) and all relevant information from the text, figures, tables and charts were extracted for analysis. Studies that contained duplicate information were included only once. Extracted data include period of the study, patient population and location. The total number of patients who underwent SOT during the study period and total number of CDI cases among them were also extracted. The median follow-up duration, methods of *C. difficile* isolation, study design, number of severe cases, and number of recurrent episodes were also included. Recurrent CDI episodes were defined as onset of symptoms after complete abatement of symptoms with proper antibiotic therapy with additional positive CDI assays. Only data about the first CDI recurrence were used for the estimation of the recurrent rate in our study population. Severe cases were represented by cases that needed surgery for colitis and/or cases that required admission in the intensive care unit due to complications directly related to CDI and/or died from CDI-related cause [10].

Quality Assessment

The methodological quality of eligible studies was assessed by two reviewers (S.P. and I.M.Z.) using the Newcastle-Ottawa Quality Assessment Scale, which is a 'star based' rating system [14]. The parameters used to evaluate the quality of individual studies were representativeness of the exposed cohort, ascertainment of exposure, demonstration that outcome of interest was not present at start of the study, assessment of outcome, follow-up long enough for outcomes to occur and adequacy of follow up of cohorts [15]. Two parameters 'selection of the non-exposed cohort' and 'comparability of cohorts on the basis of the design or analysis' were not applicable to our analysis, so each article could get up to 6 stars. We considered the study population representative of the exposed cohort if data on CDI were provided for all available transplant patients and not among a specific sub population. The outcome was assessed by the cases who presented with symptoms and laboratory diagnosis of CDI. Follow-up duration of at least 3 months was considered adequate for the outcome to occur in the cohort. Studies that received 5 stars were considered of adequate quality for extraction of relevant information.

Statistical Analysis

We performed the meta-analysis using a random-effects model to estimate the pooled prevalence and the 95% confidence intervals (CI), using Der-Simonian and Laird weights [16]. The double arcsine methodology was used to avoid an undue large weight for studies with low or high prevalence (prevalence close to 0 or 1) [17]. The Egger’s test [18,19] was used to assess small study effects. Between-study variance $\tau^2$ estimation [20] was used to assess statistical heterogeneity. Subgroup analyses were used to account for possible sources of heterogeneity. The meta and metareg commands of the Stata v13 software package (Stata Corporation, College Station, TX) were used to perform the statistical analysis. The statistical significance threshold was set at 0.05.

Results

Our literature search yielded 75,940 citations and the last day of the literature search was February 9, 2015. After scrutinizing the titles and abstracts of retrieved articles, 162 articles were accessed in full text. Among these 162 articles, 127 studies were excluded because they did not contain extractable data on prevalence of CDI among SOT patients. Of the total 35 remaining eligible studies, 10 contained partially overlapping data [21–30] and data were extracted with
an effort to extract the maximum available data. We included 30 studies in the final analysis coded from 35 articles. The details of the selection process of eligible articles are presented in the Flow chart (Fig 1).

The studies included in our analysis were published from 1991–2014 and reported data on 21,683 patients. We stratified the patients according to the type of organ transplanted. Among them 10,659 (49.2%) were kidney recipients, 5,433 (25.1%) liver, 1,556 (7.2%) lung, 1,397 (6.4%) heart, 539 (2.5%) pancreas, 60 (0.27%) intestine, 2 (0.01%) hand, 751 (3.5%) multiple- organs and 1508 (7%) were unspecified solid organ transplant recipients. Among the multiple-organ transplant recipients; combined kidney/pancreas transplant was by far the most common combination (n = 729, 97.1%). Data from individual studies are presented in Table 1 and all studies were considered of adequate quality on the basis of Newcastle-Ottawa scale (S2 Table).

Geographical location varied among the included articles. Among the 30 studies, 22 were conducted in the North America, 7 in Europe, and 1 in Asia. All studies were retrospective. Twenty one studies reported the method of isolation of C. difficile. One or more than 1 method of isolation such as stool culture and toxin detection were used in the studies. C. difficile toxin was identified using one or more of the following methods: enzyme immunoassay, radio immunoassay, tissue culture assay and PCR. The method of C. difficile isolation used in each individual study is included in Table 2.

The pooled prevalence of CDI among 21,683 SOT recipients was 7.4% [95%CI, (5.6–9.5%), $\tau^2 = 0.039$] (Fig 2). According to the Egger’s test, we found no evidence of small study effects for the overall estimated prevalence (bias: 1.93, p-value: 0.06). We also stratified our data based on the type of organ transplanted. The prevalence of CDI inpatients who underwent transplantation for more than one organ was 12.7% [95%CI, (6.4%-20.9%), $\tau^2 = 0.069$] (S1 Fig). The prevalence among other single SOT recipients was: lung transplant recipients 10.8% [95%CI, (5.5%-17.7%), $\tau^2 = 0.064$] (S2 Fig), liver 9.1% [95%CI, (5.8%-13.2%), $\tau^2 = 0.048$] (S3 Fig), intestine 8% [95% CI, (2.6%-15.9%), $\tau^2 = 0.00$] (S4 Fig), heart 5.2% [95%CI, (1.8%-10.2%), $\tau^2 = 0.042$] (S5 Fig), kidney 4.7% [95% CI, (2.6%-7.3%), $\tau^2 = 0.028$] (S6 Fig) and pancreas 3.2% [95% CI, (0.5%-7.9%), $\tau^2 = 0.030$] (S7 Fig). The differences in prevalence between kidney and liver (p-value: 0.07) and kidney and lung (p-value: 0.07) were marginally significant. The prevalence of CDI among kidney transplant recipients was also lower than intestine, heart and multiple organ recipients, but these differences did not reach statistical significance [kidney-heart (p-value: 0.83), kidney-intestine (p-value: 0.48) and kidney-multiple organs (p-value: 0.13)].

The estimated prevalence of CDI in SOT patients was 6.8% [95% CI (5.0%-9.0%), $\tau^2 = 0.032$] from studies conducted in North America and 10.5% [(4.9%-18.0%), $\tau^2 = 0.076$] from studies conducted in Europe. We also stratified the studies based on population size (<200 versus >200) and we did not find significant difference in the estimated prevalence of CDI in SOT recipients (p-value: 0.65) (Table 3).

Fifteen studies reported data on recurrence of CDI among 1,020 infected patients. Among them, 10 studies included the definition of recurrence. Three studies defined an episode as recurrent when the diagnosis was done within 8 weeks from the initial episode, 2 had a time frame longer than 8 weeks and the remaining 5 did not specify the duration (Table 2). Those studies that used a longer follow-up period to define recurrent episodes tend to overestimate the rate of recurrence. The reported recurrence rate was estimated to be 19.7% [95% CI, (13.7%-26.6%), $\tau^2 = 0.073$]. Definition of recurrence, time to recurrence, mean time to diagnosis and methods of isolation of C. difficile for individual studies are presented in the Table 2. Finally the reported prevalence of severe CDI from 19 studies was 5.3% [95% CI (2.3%-9.3%), $\tau^2 = 0.097$] and among the 1,243 C. difficile infected patients that were included in these studies there were 27 reported cases of CDI related colectomy, 37 patients had ICU admission and 20
Fig 1. Flow chart of meta-analysis.

doi:10.1371/journal.pone.0124483.g001
| Author               | Year   | Origin                          | Population                        | Study Period                      | N (Transplant recipients) | n- CDI | Recurrence (No. of cases) | Severity (No. of cases) | Quality score |
|----------------------|--------|---------------------------------|------------------------------------|-----------------------------------|---------------------------|--------|--------------------------|------------------------|---------------|
| Mittal C[38]         | 2014   | Henry Ford Hospital, Detroit, Michigan, U.S.A | Liver transplant patients         | Jan 2000- Dec 2010                | Li: 970                   | Li: 183 | 31                       | Colectomy:5             | 6             |
| Hsu JL[31]           | 2014   | University of Wisconsin, U.S.A  | Kidney or Liver transplant patients | Jan 1994- Dec 2008                | 4666 (K:3630, Li:1036)   | 170 (K:107, Li:63) | 29                       | ICU admission: 11, Colectomy:0 | 5             |
| Tsapepas DS[27]      | 2014   | Columbia University Medical Center | Single Solid organ transplant patients | Sep 2009- Dec 2012 (Median follow-up:23 months) | Li:331, Lu: 200, H:254 | Li: 9, Lu: 14, H:5 | 4                        | ICU admission/ Colectomy: NR Mortality:1 | 6             |
| Garg SI[54]          | 2014   | Johns Hopkins University, U.S.A | Liver transplant patients         | Jan 2006-Jun 2013                  | Li: 251                   | Li: 32  | 9                        | NR                     | 5             |
| Dorschner P[55]      | 2014   | Northwestern university Feinberg SoM, Chicago | Solid organ transplant patients   | Jan 2012- Jul 2012 (Follow-up: 30 days) | 146                       | 1       | NR                       | NR                     | 5             |
| Neofytos D[43]       | 2013   | Johns Hopkins Hospital, U.S.A  | Adult Kidney transplant patients  | Jan 2008-Dec 2010                 | K:603                     | K: 37    | 4                        | Colectomy/ ICU admission: 1 | 5             |
| Deshpande A[30]      | 2013   | Cleveland Clinic, Ohio, U.S.A  | Single Organ transplant patients  | Jan 2003- Dec 2009                | Lu: 525, Li: 809         | Lu: 37, Li: 69 | 5                        | ICU admission/ Colectomy: 0 Mortality: 0 | 6             |
| Wheeler M[56]        | 2013   | University of North Carolina    | Solid organ transplant patients   | 2005–2012 (Follow-up: 1 year)     | 872                       | 31      | 5                        | Colectomy: 0 Mortality: 0 | 6             |
| Kittleson M[57]      | 2013   | Sinai Heart Institute, CA, U.S.A | Adult Heart transplant patients   | 2000–2010 (Median follow-up: 1 year) | H: 554                   | H: 22    | NR                       | NR                     | 5             |
| Lee JT[25]           | 2013   | University of Minnesota, U.S.A  | Lung transplant patients          | Jan 2000-Mar 2011                 | Lu: 388                   | Lu: 89   | 36                       | Total severe cases: 5 (Colectomy:3 Mortality:2) | 6             |
| Shah SA [28]         | 2013   | Columbia University, Weill Cornell Medical Center, U.S.A | Adult Kidney or Pancreas transplant recipients | Jan 2009- Feb 2011 (Median follow-up: 291 days) | 998 (K: 942, P: 56) | 28 (K:24, P:4) | 8                        | NR                     | 6             |
| Boutros M[51]        | 2012   | McGill University Health Center, Montreal, Canada | Single or Multi-Organ transplant patients | Jan 1999- Mar 2010                | 1331 (K: 814, Li: 430, H: 112, P:109, K+P: 88, K+H:10, K+Li:7) | 165 (K:92, Li: 90, H: 9, K+P:8) | 14                       | Colectomy:6 ICU admission: 26 Mortality: 14 | 5             |
| Ott E[58]            | 2011   | Europe                          | Cardio-thoracic transplant patients | 2007–2009                          | 366                       | 21      | NR                       | Colectomy: 0             | 5             |
| Abid S[50]           | 2011   | University College of Medicine, U.S.A | Kidney or Liver transplant patients | 2005–2009                          | K: 365, Li: 41            | K:41, Li:6 | NR                       | NR                     | 6             |
| Mitu- Prebrian OM[49] | 2011   | Manchester Royal Infirmary UK    | Kidney and/or Pancreas transplant patients | Jan 2004- Dec 2007 (Follow up: 1 year) | 682 (K:576, P:18, K+P: 88) | 24 (K+P: 4, K: 20, P:0) | NR                       | Colectomy: 2             | 6             |
| Rosen JB[52]         | 2010   | Texas Children Hospital, U.S.A  | Pediatric lung transplant patients | Oct 2002–2008                      | Lu:74                     | Lu: 4    | 2                        | Ileostomy: 1             | 5             |
| Rostambeigi N[59]    | 2010   | Mayo Clinic College of Rochester, MN, USA | Adult Pancreas and/or Kidney transplant patients | Jan 1998- July 2006 (Median follow-up: 6.4 years) | 216 (K+P: 149, P: 67) | 9 (K+P:6, P:3) | 1                        | NR                     | 5             |

(Continued)
| Author             | Year | Origin                  | Population                           | Study Period                             | N (Transplant recipients) | n-CDI          | Recurrence (No. of cases) | Severity (No. of cases) | Quality score |
|--------------------|------|-------------------------|--------------------------------------|------------------------------------------|---------------------------|----------------|-------------------------|------------------------|---------------|
| Coltart IC [53]    | 2009 | King's College Hospital, UK | Liver transplant patients            | Jan 2006- April 2007                    | Li: 191                   | Li: 31         | NR                      | Colectomy: 0, Death: 0 | 5             |
| Gunderson CC [46]  | 2008 | Oschner Medical Center, Louisiana, USA | Lung transplant patients             | Nov 1990 - Nov 2005 (Median follow-up: 2.7 years) | Lu: 202                   | Lu: 15         | NR                      | Colectomy: 2       | 6             |
| Theunissen C [47]  | 2008 | Erasame University Hospital, Belgium | Adult lung transplant patients with Cystic Fibrosis | Jan 1998- Dec 2004 (Median follow-up: 4.6 years) | Lu: 49                    | Lu: 16         | NR                      | Severe cases: 5 (Surgery:2, Mortality:2) | 6             |
| Stelzmueller I [21] | 2007 | Innsbruck Medical University, Austria | Single and Multi-organ transplant patients | Jan 1994-Dec 2005                  | 2799 (K:1438, Li:651, P:289, H:242, Lu:118, H+Lu:5, I27,Intes:25, Hand:2) | 36 (K:4, L:20, P:2, H:3, Lu:4, H+Lu:5, Intes:2, Hand:1) | NR                      | Colectomy: 2 | 5             |
| Munoz P [32]       | 2007 | University of Madrid, Spain | Heart transplant patients            | Jan 1993- Dec 2005                    | H: 235                    | H: 35          | 10                     | Colectomy: 0 | 6             |
| Hashimoto M [60]   | 2007 | Tokyo University Hospital, Japan | Adult Liver transplant patients      | Jan 1996-Nov 2004                    | Li: 242                   | Li: 11         | 2                       | NR                     | 5             |
| Albright JB [81]   | 2007 | Mayo Clinic, Jacksonville, Florida, U.S.A | Liver transplant patients (cadaveric grafts) | Mar 1998-Dec 2001 | Li: 402 | Li: 32 | 7 | Colectomy: 0 | 6             |
| Michalak G [62]    | 2005 | University of Warsaw, Poland | Patients with Diabetes and end stage renal disease with Kidney and Pancreas transplant | 1998–2004 | K+P:51 | K+P:8 | NR | NR | 6             |
| Ziring D [63]      | 2005 | David Geffen School of Medicine at UCLA, CA, U.S.A | Intestine transplant patients       | Nov 1991-May 2003 (Median follow-up: 12 months) | I:33 | I:2 | NR | NR | 6             |
| Keven K [48]       | 2004 | University of Pittsburgh Medical Center, U.S.A | Adult Kidney and/or Pancreas transplant patients | Jan 1999-Dec 2002 | 702 (K: 600, K+P: 102) | 35 (K: 27, K+P: 8) | 8 (K:7, K+P:1) | Colectomy: 2 (1 death among them) | 6             |
| Loinaz C [64]      | 2003 | University of Miami, School of Medicine, Florida, U.S.A | Adult and Pediatric Intestine, Liver/Intestine or Multi visceral transplant patients | 1994–2001 | 124 | 3 | NR | NR | 6             |
| West M [49]        | 1999 | University of Minnesota, U.S.A | Adult and Pediatric Kidney and/or Pancreas transplant patients | Jan 1985-Dec 1994 | 1932 (Pediatric K:267, Adult K:1424, K+P: 251) | 159 (Pediatric K:43, Adult K:50, K+P:39) | 6 | No severe cases | 6             |
| George DL [65]     | 1991 | University of Chicago, U.S.A | Patients receiving orthotopic Liver transplant patients | Feb 1985- July 1987 (Median follow-up: 324 days) | Li: 79 | Li: 2 | NR | NR | 6             |

**Footnotes:** H: Heart, I: Intestine, ICU: Intensive Care Unit, K: Kidney, Li: Liver, Lu: Lungs, NR: Not reported, P: Pancreas.
patients died due to CDI related complications. The prevalence of colectomy due to CDI related complications in our study was 2.7% [95% CI (1.3%-4.6%), $\tau^2 = 0.023$]. Due to limited data on individual cases that required ICU admission and/or died, statistical representation could not be done in our analysis.

**Discussion**

*C. difficile* infection has been increasingly recognized among SOT recipients [31]. The estimated prevalence of CDI in SOT patients in our study was 7.4%, which is higher than the 0.9% reported in the general hospital population [2]. In our study, lung and liver transplant patients had higher prevalence of CDI compared to kidney transplant recipients and this difference was marginally significant. There was no significant difference in the prevalence based on the size of the study population. Recurrence of CDI episodes was seen in 19.7% of cases and 5.3% of patients had severe CDI resulting in colectomy, ICU admission or death.

The overall estimated prevalence of CDI in our study is almost 3 times higher than that reported in a previous study which used data from 2009 nationwide inpatient sample database (2.7%) [10]. The fact that we included data from the initial hospitalization after transplantation might be the reason for the higher overall estimated prevalence. Indeed, most cases of CDI among SOT recipients are diagnosed in the early post-transplantation period due to intense immunosuppression, more frequent antimicrobial exposure and increased exposure to the health care setting [7]. The observed difference might also be due to the long duration of follow-up in the studies included in our meta-analysis as the follow-up time in most of our studies was up to several months and even years after transplantation.

In agreement to the study that reported the data from nationwide inpatient sample database [10], the prevalence of CDI was higher among lung transplant recipients in comparison to the kidney transplant patients. This might be attributed to the higher level of immunosuppression required for lung transplant patients [24]. Also, lung transplant patients often have a history of prolonged exposure to antibiotics and frequent hospital admissions, increasing their risk for CDI [25]. Also, patients who underwent transplantation of more than one organ had more than 3-times higher point prevalence of CDI than kidney recipients in our study, but this difference did not reach statistical significance, possibly due to the limited number of cases of multi-organ transplant patients.

Recurrence is a common problem in SOT patients with CDI [32]. Recurrent CDI can occur either because of relapse or because of re-infection; the relative frequency of each of these mechanism has not been well described [33]. Risk factors, such as increased length of hospital stay, prolonged use of antibiotics, immunosuppression and co-morbid conditions are associated with recurrence of CDI in SOT recipients [31,34] and, the recurrence rate varies based on the treatment of the initial CDI episode [35]. The estimated recurrence rate of CDI in our study was 19.7%, and it was comparable to the median 21.6% that was recently reported in a relevant meta-analysis in the general hospital setting [36].

Knowledge on the outcomes of CDI in SOT recipient is remarkably limited [37]. Few studies have reported an increase in the in hospital mortality, a longer hospital stay and cost of health care services among this group of patients [10,38]. CDI can also result in complications requiring colectomy and ICU admission [10]. Among the studies that reported data on severity, at least 5.3% of the patients had complications related to CDI in compared to 3%-5% rate of fulminant colitis in total hospitalized *C. difficile* infected patients [9,39,40]. The prevalence of colectomy in SOT patients due to CDI related complications in our study was 2.7% compared with 0.7% reported from the national inpatient sample database analysis in the general hospital population from 2001–2010 [41].
| Author       | Year | Follow-up          | Recurrence (No. of cases) | Recurrence (definition)                                                                 | Method of diagnosis                                                                 | Time of CDI diagnosis |
|--------------|------|--------------------|---------------------------|----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-----------------------|
| Mittal C     | 2014 | NR                 | 31                        | New onset of diarrhea or positive stool toxin assay within 12 weeks of CDI              | Until 2008: EIA for toxin A/B, From 2009: Glutamate dehydrogenase followed by EIA and molecular testing | Mean: 51 days         |
| Hsu JL       | 2014 | NR                 | 29                        | Episodes of CDI < 8 weeks after resolution of symptoms from previous episode          | Positive CD culture and stool toxin, pseudomembranous colitis on endoscopy/ histopathology | Mean: 653 days        |
| Tsapepas DS  | 2014 | Median follow-up: 23 months (16–31 months) | 4                        | Resurgence of diarrhea after the cessation of initial therapy, confirmed by a subsequent stool specimen with detection of Clostridium difficile toxin B by PCR | Toxin detection by PCR                                                          | 51 days               |
| Garg S       | 2014 | NR                 | 9                         | More than 1 episode of CDI in an OLT recipient at any time after OLT                  | Cytotoxin assay or PCR for toxin gene B                                              | NR                    |
| Dorschner P  | 2014 | 30 days            | NR                        | New episode of CDI after at least 14 completed days of treatment for primary CDI     | Cytotoxin assay for toxins A and B or PCR                                            | Mean: 9 days          |
| Neofytos D   | 2013 | 6 months           | 4                         | CDI diagnosed using the same criteria as for the first episode and occurring after an initial CDI episode has resolved completely with treatment | Toxin detection by EIA                                                              | Median: 116 days (Lung transplant patients), 23 days (Liver transplant patients) |
| Deshpande A  | 2013 | NR                 | Data on recurrent episodes | CDI diagnosed using the same criteria as for the first episode and occurring after an initial CDI episode has resolved completely with treatment | Toxin detection by EIA                                                              | Median: 57 days       |
| Wheeler M    | 2013 | 1 year             | 5                         | Reappearance of CDI within 2 months                                                  | Not Specified                                                                       | 26 days               |
| Kittleson M  | 2013 | 1 year             | 1                         | NR                                      | NR                                                                                   | NR                    |
| Lee JT       | 2013 | Median follow-up: 4.2 years | 36                       | Recurrence of symptoms with positive CDI assay after complete abatement of symptoms with antibiotics | Until 2007: Stool culture and toxin assay with EIA, From 2007: Toxin assay and PCR      | 177 days (4 days-6.9 years) |
| Shah SA      | 2013 | Median follow-up: 291 days | 8                        | Recurrence of symptoms with positive CD PCR between 6-50 days after stopping treatment | Gene B PCR                                                                           | Median: 57 days       |
| Boutros M    | 2012 | NR                 | 14                        | Two clinical episodes of CDI (with positive cytotoxin assay) more than two months apart | Cell culture cytotoxin assay for toxin B                                              | NR                    |
| Ott E        | 2011 | NR                 | NR                        |                                          |                                                                                       | NR                    |
| Abid S       | 2011 | NR                 | NR                        |                                          |                                                                                       | NR                    |
| Mitu-Pretorian OM | 2011 | NR             | NR                        |                                          |                                                                                       | NR                    |
| Rosen B      | 2010 | NR                 | 2                         |                                          |                                                                                       | NR                    |
| Rostambeigi N| 2010 | 6.4 years          | 1                         |                                          |                                                                                       | NR                    |
| Coltart IC   | 2009 | 90 days            | NR                        |                                          |                                                                                       | 15.5 days             |
| Gunderson CC | 2008 | 2.7 years          | NR                        |                                          |                                                                                       | NR                    |
| Theunissen C | 2008 | 4.6 years          | NR                        |                                          |                                                                                       | NR                    |
| Stelzmueller I | 2007 | NR                  | NR                        |                                          | Until 1995: Stool culture and toxin assay with RIA; From 1996: Stool culture and toxin assay with EIA | NR                    |
| Munoz P      | 2007 | 50 days            | 10                        |                                          | Stool culture and CD toxin B by cell culture cytotoxin test                           | Mean: 32 days         |

(Continued)
To locate possible sources of heterogeneity, we performed a subgroup analysis based on the size of the study population. Studies with small population size tend to overestimate the outcome. To evaluate this effect we stratified the studies based on population size (≥200 versus <200). The size of study population, however, did not significantly alter the estimated prevalence of CDI in SOT recipients (Table 3).

Notably, there were certain limitations in our study. Most of the studies that were included in our meta-analysis had a long study period (>6 years) and did not report the prevalence of CDI stratified by year. Therefore, it was not feasible to estimate the trend over time, so it is likely that the number of CDI cases in the recent times can be even higher. The follow-up period varied widely among studies included in our analysis making a sub-analysis of the data based on follow-up duration not possible. However, out of 13 studies that reported the mean time to CDI diagnosis, only 3 had a mean time of more than 3 months with the remaining 10 studies having a mean time to diagnosis within 3 months, supporting that most of the recorded episodes of CDI occurred shortly after SOT. Detection methods used to diagnose CDI among the studies included in our analysis differ in sensitivity [42]. Two or more methods of isolation of *Clostridium difficile* were used in most of the studies and during different time frames, but the studies did not provide stratified extractable data. Therefore, a sensitivity analysis based on the diagnostic methods used was not feasible. Also, the definition of recurrence varied between studies [24,31,38,43] and in 2 of them the time to relapse of symptoms used for defining recurrent cases was longer than the 8 weeks used in current clinical practice guidelines for *Clostridium difficile* infection in adults [44]. The latter studies tend to overestimate the number of recurrent cases and therefore the estimated prevalence of recurrence in our study might not be a precise estimate as per the current clinical practice guidelines. The estimated recurrence rate in our study is a pooled data from studies using different treatment modalities, so different rate of treatment failure and recurrence might exist in each individual study. Twenty studies in our analysis mentioned possible risk factors associated with CDI in SOT recipients. They described prolonged exposure to antibiotics [27,43,45–50], immunosuppression [21,46,48–51] and

### Table 2. (Continued)

| Author     | Year | Follow-up | Recurrence (No. of cases) | Recurrence (definition) | Method of diagnosis                                                                 | Time of CDI diagnosis |
|------------|------|-----------|---------------------------|-------------------------|-------------------------------------------------------------------------------------|-----------------------|
| Hashimoto M| 2007 | 3 months  | 2                         | NR                      | Stool culture, ICA for CD toxin A, latex test for CD protein glutamate dehydrogenase | Mean: 19 days         |
| Albright JB| 2007 | 5 days-1999 days | 7                         | NR                      | EIA for toxin A and B                                                               | NR                    |
| Michalak G | 2005 | NR        | NR                        | NR                      | NR                                                                                  | NR                    |
| Ziring D   | 2005 | 12 months (2 months-69 months) | NR                       | NR                      | CD toxin Immunoassay                                                                | NR                    |
| Keven K    | 2004 | NR        | 8                         | NR                      | CD toxin assay                                                                     | 30 days               |
| Loinaz C   | 2003 | 535±58.12 days | NR                       | NR                      | NR                                                                                  | NR                    |
| West M     | 1999 | 6         | NR                        | NR                      | Stool culture or CD toxin assay                                                     | NR                    |
| George DL  | 1991 | 324 days (70 days-883 days) | NR                       | NR                      | NR                                                                                  | NR                    |

**Footnotes:** CD: *Clostridium difficile*, CDI: *Clostridium difficile* infection, EIA: enzyme immunoassay, ICA: immune chromatographic assay, NR: not reported, PCR: polymerase chain reaction, RIA: radio immunoassay

DOI:10.1371/journal.pone.0124483.t002
Table 3. Summary Estimates.

| CDI                     | Studies (arms) | N    | Combined Effect (95% CI)                  | $\tau^2$ | P-value |
|-------------------------|----------------|------|------------------------------------------|---------|---------|
| All Studies             | 30 (35)        | 21,683 | 7.4% [95% CI, (5.6-9.5%)]                | 0.039   | Ref     |
| Kidney                  | 9              | 10,659 | 4.7% [95% CI (2.6-7.3%)]                 | 0.028   | Ref     |
| Liver                   | 12             | 5,433  | 9.1% [95% CI (5.8-13.2%)]                | 0.048   | 0.07    |
| Lungs                   | 7              | 1,556  | 10.8% [95% CI (5.5-17.7%)]               | 0.064   | 0.07    |
| Heart                   | 6              | 1,397  | 5.2% [95% CI (1.8-10.2%)]                | 0.042   | 0.83    |
| Pancreas                | 4              | 539    | 3.2% [95% CI (0.5-7.9%)]                 | 0.030   | 0.54    |
| Intestine               | 2              | 60     | 8.0% [95% CI (2.6-15.9%)]                | 0.000   | 0.48    |
| Multiple Organ          | 7              | 751    | 12.7% [95% CI (6.4-20.9%)]               | 0.069   | 0.13    |
| Geographical region     |                |        |                                          |         |         |
| North America           | 22             | 15,737 | 6.8% [95% CI (5.0-9.0%)]                 | 0.032   | Ref     |
| Europe                  | 7              | 5,704  | 10.5% [95% CI (4.9-18.0%)]               | 0.076   |         |
| Populations             |                |        |                                          |         |         |
| ≥200 patients           | 22             | 20,936 | 7.1% [95% CI (5.2-9.4%)]                 | 0.037   | Ref     |
| <200 patients           | 8              | 747    | 8.6% [95% CI (3.2-16.1%)]                | 0.099   | 0.65    |
increased days of hospitalization [26,27,38,43,45,46,50,52,53] to be associated with CDI. However, due to lack of raw data on each risk factor, statistical representation could not be performed in our study. Importantly, infection control measures and local epidemiology have a significant role in the prevalence of CDI among individual centers and our pooled estimation does not decrease the need of each local center to know the local prevalence.

In conclusion, our analysis estimated the pooled prevalence of CDI among SOT recipients to be almost 3 times higher than previously indicated. The observed high prevalence of CDI, along with the significant rate of severe cases, highlights the need for preventive policies, such as antimicrobial stewardship programs, strict compliance with hand hygiene and environmental decontamination that specifically target this patient population. Also, studies are needed to identify immunosuppressive and prophylactic antimicrobial regimens that are probably associated with lower risk of CDI.

Supporting Information

S1 Fig. Prevalence of CDI among multiple solid organ transplant recipients.
(TIF)
S2 Fig. Prevalence of CDI among lung transplant recipients.
(TIF)
S3 Fig. Prevalence of CDI among liver transplant recipients.
(TIF)
S4 Fig. Prevalence of CDI among intestine transplant recipients.
(TIF)
S5 Fig. Prevalence of CDI among heart transplant recipients.
(TIF)
S6 Fig. Prevalence of CDI among kidney transplant recipients.
(TIF)
S7 Fig. Prevalence of CDI among pancreas transplant recipients.
(TIF)
S1 Table. PRISMA checklist.
(PDF)
S2 Table. Quality Assessment.
(PDF)

Author Contributions

Conceived and designed the experiments: SP IMZ EM. Analyzed the data: IMZ FNZ. Wrote the paper: SP IMZ FNZ PDZ EM. Performed literature search: SP IMZ. Quality analysis: SP IMZ. Interpreted the results: FNZ IMZ PDZ SP EM.

References

1. Miller BA, Chen LF, Sexton DJ, Anderson DJ. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile Infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol. 2011; 32:387–390. doi: 10.1086/659156 PMID: 21460491
2. Lucado J, Gould C, Elixhauser A. Clostridium Difficile Infections (CDI) in Hospital Stays, 2009: Statistical Brief #124. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD): Agency for Health Care Policy and Research (US). 2006

3. Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000–2005. Emerg Infect Dis. 2008; 14: 929–931. doi:10.3201/eid1406.071447 PMID: 18507904

4. Goudarzi M, Seyedjavadi SS, Goudarzi H, Meh dizadeh Aghdam E, Nazeri S. Clostridium difficile Infection: Epidemiology, Pathogenesis, Risk Factors, and Therapeutic Options. Scientifica (Cairo) 2014:2014. doi:10.1155/2014/916826 PMID: 24991448

5. Hall AJ, Curns AT, McDonald LC, Parashar UD, Lopman BA. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999–2007. Clin Infect Dis. 2012; 55: 216–223. doi:10.1093/cid/cis386 PMID: 22491338

6. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis. 2012; 55 Suppl 2: S88–92. doi:10.1093/cid/cis335 PMID: 22752870

7. Len O, Rodriguez-Pardo D, Gavalda J, Aguado JM, Blanes M, Borrell N et al. Outcome of Clostridium difficile-associated disease in solid organ transplant recipients: a prospective and multicentre cohort study. Transpl Int. 2012; 25: 1275–1281. doi:10.1111/j.1432-2277.2012.01568.x PMID: 23039822

8. Honda H, Dubberke ER. Clostridium difficile infection in solid organ transplant recipients. Curr Opin Infect Dis. 2014; 27: 336–341. doi:10.1097/QCO.0000000000000075 PMID: 24927151

9. Dallal RM, Harbrecht BG, Boujoukas AJ, Sirio CA, Farkas LM, Lee KK et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg. 2002; 235: 368–372. PMID: 11882758

10. Pant C, Anderson MP, O'Connor JA, Marshall CM, Deshpande A, Sferra TJ et al. Association of Clostridium difficile infection with outcomes of hospitalized solid organ transplant recipients: results from the 2009 Nationwide Inpatient Sample database. Transpl Infect Dis. 2012; 14: 540–547. doi:10.1111/j.1399-3062.2012.00761.x PMID: 22726461

11. Group JAMA. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283: 2008–2012. PMID: 10789670

12. Wallia A, Parikh ND, Molitch ME, Mahler E, Tian L, Huang JJ et al. Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection. Transplantation. 2010; 89: 222–226. doi: 10.1097/TP.0b013e3181c3c2ff PMID: 2098286

13. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010; 31: 431–455. doi:10.1086/651706 PMID: 20307191

14. Wells G, Shea B, O'connell D, Peterson J, Welch V, Losos M et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000 doi:10.1371/journal.pntd.0002195 PMID: 23658850

15. Zacharioudakis IM, Ziakas PD, Mylonakis E. Clostridium difficile infection in the hematopoietic unit: a meta-analysis of published studies. Biol Blood Marrow Transplant. 2014; 20: 1650–1654. doi:10.1016/j.bbmt.2014.06.001 PMID: 24914822

16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177–188. PMID: 3802833

17. Pull SR, Graumlich JF, Pamulaparthy SR, Kalva N. Endoscopic transmural necrosectomy for walled-off pancreatic necrosis: a systematic review and meta-analysis. Can J Gastroenterol Hepatol. 2014; 28: 50–53. PMID: 24212912

18. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315: 629–634. PMID: 9310563

19. Ziakas PD, Plakos EE, Zervou FN, Knoll BM, Rice LB, Mylonakis E. MRSA and VRE colonization in solid organ transplantation: a meta-analysis of published studies. Am J Transplant. 2014; 14: 1887–1894. PMID: 25040438

20. Rucker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I(2) in assessing heterogeneity may mislead. BMC Med Res Methodol. 2008; 8: 79. doi:10.1186/1471-2288-8-79 PMID: 19036172

21. Stelzmueller I, Goerge H, Biebl M, Wiesmayr S, Berger N, Tabarelli W et al. Clostridium difficile colitis in solid organ transplantation—a single-center experience. Dig Dis Sci. 2007; 52: 3231–3236. PMID: 17406820
22. Stelzmueller I, Wiesmayr S, Eller M, Fille M, Lass-Floerl C, Weiss G et al. Enterocolitis due to simultaneous infection with rotavirus and Clostridium difficile in adult and pediatric solid organ transplantation. J Gastrointest Surg. 2007; 11: 911–917. PMID: 17440792

23. Berger N, Wirmserberger R, Kafka R, Margreiter C, Ebenbichler C, Stelzmueller I et al. Infectious complications following 72 consecutive enteric-drained pancreas transplants. Transpl Int. 2006; 19: 549–557. PMID: 16764633

24. Lee JT, Hertz MI, Dunitz JM, Kelly RF, D'Cunha J, Whitson BA et al. The rise of Clostridium difficile infection in lung transplant recipients in the modern era. Clin Transplant. 2013; 27: 303–310. doi: 10.1111/ctr.12064 PMID: 23316931

25. Lee JT, Kelly RF, Hertz MI, Dunitz JM, Shumway SJ. Clostridium difficile infection increases mortality risk in lung transplant recipients. J Heart Lung Transplant. 2013; 32: 1020–1026. doi: 10.1016/j.healun.2013.06.012 PMID: 23890202

26. Lee JT, Whitson BA, Kelly RF, D'Cunha J, Dunitz JM, Hertz MI et al. Calcineurin inhibitors and Clostridium difficile infection in adult lung transplant recipients: the effect of cyclosporine versus tacrolimus. J Surg Res. 2013; 184: 599–604. doi: 10.1016/j.jss.2013.03.041 PMID: 23566442

27. Tsapepas DS, Martin ST, Miao J, Shah SA, Scheffert J, Fester K et al. Clostridium difficile infection, a descriptive analysis of solid organ transplant recipients at a single center. Diagn Microbiol Infect Dis. 2014

28. Shah SA, Tsapepas DS, Kubin CJ, Martin ST, Mohan S, Ratner LE et al. Risk factors associated with Clostridium difficile infection after kidney and pancreas transplantation. Transplant Infect Dis. 2013; 15: 502–509. doi: 10.1111/tid.12113 PMID: 23847612

29. Esef JM, Hanouneh IA, Koval CE, Kovacs C, Dalal DS, Ansari-Gilani K et al. Impact of pretransplant rifaximin therapy on early post-liver transplant infections. Liver Transplant. 2014; 20: 544–551. doi: 10.1002/lt.23845 PMID: 24493238

30. Deshpande A, Pasupuleti V, Mossad SB, Budev M, Schmitt SK, Corey RB et al. Use of Lactobacillus in Prevention of Recurrences of Clostridium difficile Infection in Solid Organ Transplant Recipients. Infectious Diseases in Clinical Practice. 2013; 21: 292–298.

31. Hsu JL, Enser JJ, McKown T, Leverson GE, Pirsch JD, Hess TM et al. Outcomes of Clostridium difficile infection in recipients of solid abdominal organ transplants. Clin Transplant. 2014; 28: 267–273. doi: 10.1111/ctr.12309 PMID: 24474612

32. Munoz P, Giannella M, Alcala L, Sarmiento E, Fernandez Yanez J, Palomo J et al. Clostridium difficile-associated diarrhea in heart transplant recipients: is hypogammaglobulinemia the answer? J Heart Lung Transplant. 2007; 26: 907–914. PMID: 17845929

33. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect. 2009; 58: 403–410. doi: 10.1016/j.jinf.2009.03.010 PMID: 19394704

34. Gellad ZF, Alexander BD, Liu JK, Griffith BC, Meyer AM, Johnson JL et al. Severity of Clostridium difficile-associated diarrhea in solid organ transplant patients. Transpl Infect Dis. 2007; 9: 276–280. PMID: 17635835

35. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011; 364: 422–431. doi: 10.1056/NEJMoa0910812 PMID: 21288078

36. Deshpande A, Pasupuleti V, Thota P, Pant C, Rolston DD, Hernandez AV et al. Risk Factors for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-Analysis. Infect Control Hosp Epidemiol: 1–9.2015

37. Riddle DJ, Dubberke ER. Clostridium difficile infection in the intensive care unit. Infect Dis Clin North Am. 2009; 23: 727–743. doi: 10.1016/j.idc.2009.04.011 PMID: 19665092

38. Mittal C, Hassan S, Arshad S, Jeepalyam S, Bruni S, Miceli M et al. Clostridium difficile infection in liver transplant recipients: a retrospective study of rates, risk factors and outcomes. Am J Transplant. 2014; 14: 1901–1907. doi: 10.1111/ajt.12798 PMID: 24902610

39. Wysowski DK. Increase in deaths related to enterocolitis due to Clostridium difficile in the United States, 1999–2002. Public Health Rep. 2006; 121: 361–362. PMID: 16827436

40. Longo WE, Mazuski JE, Virgo KS, Lee P, Bahadursingh AN, Johnson FE. Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum. 2004; 47: 1620–1626. PMID: 15540290

41. Halabi WJ, Nguyen VQ, Carmichael JC, Pigazzi A, Stamos MJ, Mills S et al. Clostridium difficile colitis in the United States: a decade of trends, outcomes, risk factors for colectomy, and mortality after colectomy. J Am Coll Surg. 2013; 217: 802–812. doi: 10.1016/j.jamcollsurg.2013.05.028 PMID: 24011436

42. Planche TD, Davies KA, Coen PG, Finney JM, Monahan IM, Morris KA et al. Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C
44. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC et al. Clinical practice guidelines for Clostridium difficile infection in kidney transplant recipients. Transplant Infect Dis.2013; 15: 134–141. doi: 10.1111/tid.12030 PMID: 23173772

45. Mitu Pretorian OM, Forgacs B, Qumruddin A, Tavakoli A, Augustine T, Pararajasingham R et al. Outcomes of patients who develop symptomatic Clostridium difficile infection after solid organ transplantation. Transplant Proc.2010; 42: 2631–2633. doi: 10.1016/j.transproceed.2010.04.057 PMID: 20832558

46. Gunderson CC, Gupta MR, Lopez F, Lombard GA, LaPlace SG, Taylor DE et al. Clostridium difficile colitis in lung transplantation. Transplant Infect Dis.2008; 10: 245–251. doi: 10.1111/j.1399-3062.2008.00305.x PMID: 18312477

47. Theunissen C, Knoop C, Nonhoff C, Byl B, Claus M, Liesnard C et al. Clostridium difficile colitis in cystic fibrosis patients with and without lung transplantation. Transpl Infect Dis.2008; 10: 240–244. doi: 10.1016/j.transproceed.2010.04.057 PMID: 17630999

48. Keven K, Basu A, Re L, Tan H, Marcos A, Fung JJ et al. Clostridium difficile colitis in patients after kidney and pancreas-kidney transplantation. Transpl Infect Dis.2004; 6: 10–14. PMID: 15225221

49. West M, Pirene J, Chavera B, Gillingham K, Sutherland DE, Dunn DL et al. Clostridium difficile colitis after kidney and kidney-pancreas transplantation. Clin Transplant.1999; 13: 318–323. PMID: 10485373

50. Abid S, Kohli P, Haleem S, Shahid N, Gupta M, Sass D et al. Clostridium difficile associated diarrhea in patients with kidney and liver transplantation. American Journal of Transplantation.2011; 11: 324.

51. Boutros M, Al-Shaibi M, Chan G, Cantarovich M,rame, E, Paraskevas S et al. Clostridium difficile colitis: increasing incidence, risk factors, and outcomes in solid organ transplant recipients. Transplantation.2012; 93: 1051–1057. doi: 10.1097/TP.0b013e31824d34de PMID: 22441318

52. Rosen JB, Schecter MG, Heinle JS, McKenzie ED, Morales DL, Dishop MK et al. Clostridium difficile colitis in children following lung transplantation. Pediatr Transplant.2010; 14: 651–656. doi: 10.1111/j.1399-3062.2010.01314.x PMID: 20561346

53. Coltart IC, Stoessner N, Gera A, Verma A, Sizer E, Auzinger G et al. Prevalence of Clostridium difficile associated diarrhoea after liver transplantation and risk factors for its development: A UK-based single centre case control study. Gut.2009; 58: A69.

54. Garg S, Wozniak A, Shoham S, Hamilton JP, Gurakar A. Clostridium difficile infection among patients who have undergone orthotopic liver transplantation. Gastroenterology.2014; 146: S–942.

55. Dorschner P, McElroy L, Ladner D, Ison M. A retrospective study of early post-transplant nosocomial infections. Transplantation.2014; 98: 776.

56. Wheeler M, Deyo J, Huang J, Lee R, Kozloski T, Dupuis R et al. Incidence, risk factors, and response rate to initial therapy for clostridium difficile in solid organ transplant recipients. American Journal of Transplantation.2013; 13: 344.

57. Kittleson M, Patel J, Rafiei M, Osborne A, Moradzadeh A, Chang D et al. The development of clostridium difficile in heart transplant patients on different immunosuppression regimens. Journal of Heart and Lung Transplantation.2013; 32: S131.

58. Ott E, Fegbeutel C, Warnecke G, Mattner F. Incidences of C. difficile infections in cardiothoracic transplant recipients. Clinical Microbiology and Infection.2011; 17: S774–S775.

59. Rostamebigi N, Kudva YC, John S, Mailankody S, Pedersen RA, Dean PG et al. Epidemiology of infections requiring hospitalization during long-term follow-up of pancreas transplantation. Transplantation.2010; 89: 1126–1133. doi: 10.1097/TP.0b013e3181d54bb9 PMID: 20164817

60. Hashimoto M, Sugawara Y, Tamura S, Kaneko J, Matsui Y, Togashi J et al. Clostridium difficile-associated diarrhea after living donor liver transplantation. World J Gastroenterol.2007; 13: 2072–2076. PMID: 17465450

61. Albright JB, Bonatti H, Mendez J, Kramer D, Stauffer J, Hinder R et al. Early and late onset Clostridium difficile-associated colitis following liver transplantation. Transpl Int.2007; 20: 866–866. PMID: 17854444

62. Michalak G, Kwiatkowski A, Bieniasz M, Meszaros J, Czerwinski J, Wszola M et al. Infectious complications after simultaneous pancreas-kidney transplantation. Transplant Proc.2005; 37: 3560–3563. PMID: 16298661
63. Ziring D, Tran R, Edelstein S, McDiarmid SV, Gajjar N, Cortina G et al. Infectious enteritis after intestinal transplantation: incidence, timing, and outcome. Transplantation. 2005; 79: 702–709. PMID: 15785377

64. Loinaz C, Kato T, Nishida S, Weppler D, Levi D, Dowdy L et al. Bacterial infections after intestine and multivisceral transplantation. Transplant Proc. 2003; 35: 1929–1930. PMID: 12962852

65. George DL, Arnow PM, Fox AS, Baker AL, Thistlethwaite JR, Emond JC et al. Bacterial infection as a complication of liver transplantation: epidemiology and risk factors. Rev Infect Dis. 1991; 13: 387–396. PMID: 1866541